CompanyDeals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

CompanyDrug

CARsgen Therapeutics Secures World’s First Solid Tumor CAR-T Approval with Kylimei for Gastric Cancer

CompanyDeals

Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs

CompanyDeals

MacroGenics Secures $24.5M Milestone from Sanofi Following FDA Approval Expansion for Tzield in Type 1 Diabetes

CompanyDrug

Pfizer Reports Mixed Phase 3 Results for Sigvotatug Vedotin in Non-Small Cell Lung Cancer

Policy / Regulatory

Anhui Province Launches National Alliance for Monoclonal Antibody Biologics Volume-Based Procurement

CompanyDeals

Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager

CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player
CompanyDeals

CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player

CompanyDeals

Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer

CompanyDrug

Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio

CompanyDrug

Mabwell Bioscience Presents Promising Phase I/II Data for Nectin-4 ADC Bulumtatug Fuvedotin in Cervical Cancer at ESMO-GC

CompanyDrug

Innovent Biologics Doses First Patient in Pivotal Phase III Trial for IBI3003 Trispecific Antibody in Relapsed/Refractory Multiple Myeloma